A phase i study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

Investigational New Drugs

Volumn 34, Issue 2, 2016, Pages 168-175

  Deming, Dustin A ^a   Cavalcante, Ludmila L ^a   Lubner, Sam J ^a   Mulkerin, Daniel L ^a   Loconte, Noelle K ^a   Eickhoff, Jens C ^a   Kolesar, Jill M ^a   Fioravanti, Suzanne ^b   Greten, Tim F ^b   Compton, Kathryn ^b   Doyle, Austin G ^b   Wilding, George ^a   Duffy, Austin ^b   Liu, Glenn ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AZD6244; Cetuximab; Colon cancer; KRAS; Phase I; Selumetinib

Indexed keywords

CETUXIMAB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; SELUMETINIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P21;

ACNE; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TONSIL CARCINOMA; VOLUME OF DISTRIBUTION; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CETUXIMAB; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84961063545     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0314-7     Document Type: Article

References (17)

1. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
2. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
3. Benvenuti S, Sartore-Bianchi A, Nicolantonio DI F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648
4. Souglakos J, Philips J, Wang R et al (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101:465-472
5. Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856-862
6. Nicolantonio DI F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712
7. Yeh TC, Marsh V, Bernat BA et al (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576-1583
8. Davies BR, Logie A, Mckay JS et al (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209-2219
9. Adjei AA, Cohen RB, Franklin W et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146
10. Banerji U, Camidge DR, Verheul HM et al (2010) The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): A phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16:1613-1623
11. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (Version 1.1). Eur J Cancer 45:228-247
12. Ikesue H, Vermeulen LC, Hoke R et al (2010) Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags. Am J Health Syst Pharm 67:223-226
13. Ballif BA, Blenis J (2001) Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12:397-408
14. Corcoran RB, Atreya CE, Falchook GS et al (2014) Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J Clin Oncol 32:5s (suppl; abstr 3517)
15. Bendell JC, Atreya CE, Theirry A et al Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 32:5s (suppl; abstr 3515)
16. Van Geel R, Elez E, Bendell JC, et al (2014) Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-Specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 32:5s (suppl; abstr 3514)
17. Hong DS, Van Karlyle M, Fu S, et al (2014) Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 32:5s (suppl; abstr 3516)